EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach

Oliver Pfaar iD, Ralph Mösges iD, Michael S Blaiss iD, Sven Becker iD, Lawrence DuBuske iD, Jonathan A Bernstein iD, Uwe E Berger iD, Markus Berger iD, Stephanie Dramburg iD, Mohamed H Shamji iD, Anke Graessel iD, Sviatlana Starchenka iD und 6 weitere

Allergy · 2025-12 · 80 (12) · 3369-3376

DOI: 10.1111/all.16654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 18.07.2025. Verfasst von Oliver Pfaar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg…. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Minimal Clinically Important Difference, Allergens, Rhinitis, Allergic, Seasonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergy Therapeutics Plc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Regulatory authorities recommend a combination of symptom and medication scores during the grass pollen season as a primary endpoint for Phase III allergen immunotherapy (AIT) trials targeting allergic rhinoconjunctivitis. However, many composite primary endpoint scales exist; none are validated, nor do they have a well‐justified minimal clinically important difference (MCID).

Methods

Direct patient feedback from 1071 grass‐allergic patients was obtained to determine the minimally relevant improvement in allergic symptoms and translated into an MCID for the EAACI recommended CSMS 0–6 . Additionally, a clinically relevant threshold for the validated Rhinitis Quality of Life Questionnaire (RQLQ(S)) was determined from studies of registered SLIT products and subsequently used as an anchor to derive the MCID for CSMS 0–6 using the data of a Phase III clinical trial with PQ Grass 27,600 SU (RESONATE).

Results

69% of grass‐allergic patients were satisfied with a 1‐point‐improvement (e.g., from “severe” to “moderate”) in their most severe symptom. This translated into an MCID range for CSMS 0–6 of −0.23 to −0.21 points or −17% to −16%. Furthermore, a −0.34 point difference in RQLQ(S) compared to placebo was justified as clinically meaningful based on Phase III data from 2 registered SLIT grass tablets. Using this RQLQ(S) threshold as an anchor, an MCID of CSMS 0–6 of −0.21 points (−16%) was derived using RESONATE.

Conclusions

Both patient feedback and RESONATE results support an average MCID of −0.22 points on the CSMS 0–6 scale and −16% on a composite primary endpoint scale, providing minimal thresholds to be achieved after AIT compared to placebo to conclude a positive Phase III trial outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicMinimal Clinically Important DifferenceAllergensRhinitis, Allergic, SeasonalHumansQuality of LifeTreatment OutcomeFemaleMaleAdultSurveys and QuestionnairesEvidence-Based MedicineMiddle AgedPoaceaeAdolescentYoung Adult

Stichwörter der Autor:innen

EAACI CSMS0–6allergic rhinoconjunctivitisgrass pollen allergypivotal phase III clinical trialsubcutaneous immunotherapy

Substanzen

Allergens

Autor:innen und Institutionen

  • Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
  • IMSB, Medical Faculty University at Cologne, Cologne, Germany.
  • ClinCompetence Cologne GmbH, Cologne, Germany.
  • Division of Allergy and Immunology, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of Eberhard-Karls University Tuebingen, Tuebingen, Germany.
  • George Washington University Hospital, Washington, District of Columbia, USA.

ORCID-Profile: Oliver Pfaar, Ralph Mösges, Michael S Blaiss, Sven Becker, Lawrence DuBuske, Jonathan A Bernstein, Uwe E Berger, Markus Berger, Stephanie Dramburg, Mohamed H Shamji, Anke Graessel, Sviatlana Starchenka, Katrin Birkholz, Oliver Armfield, Matthias F Kramer, Murray A Skinner, Pieter-Jan de Kam

Förderung

  • Allergy Therapeutics Plc.

Zitieren

APA

Pfaar, O., Mösges, R., Blaiss, M. S., Becker, S., DuBuske, L., Bernstein, J. A., Berger, U. E., Berger, M., Dramburg, S., Shamji, M. H., Graessel, A., Starchenka, S., Birkholz, K., Armfield, O., Sellwood, F., Kramer, M. F., Skinner, M. A., & de Kam, P. J. (2025). The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach. Allergy, 80(12), 3369-3376. https://doi.org/10.1111/all.16654

Vancouver

Pfaar O, Mösges R, Blaiss MS, Becker S, DuBuske L, Bernstein JA, et al. The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach. Allergy. 2025;80(12):3369-3376. doi:10.1111/all.16654

BibTeX
@article{Pfaar2025,
  author = {Pfaar, Oliver and Mösges, Ralph and Blaiss, Michael S and Becker, Sven and DuBuske, Lawrence and Bernstein, Jonathan A and Berger, Uwe E and Berger, Markus and Dramburg, Stephanie and Shamji, Mohamed H and Graessel, Anke and Starchenka, Sviatlana and Birkholz, Katrin and Armfield, Oliver and Sellwood, Fiona and Kramer, Matthias F and Skinner, Murray A and de Kam, Pieter-Jan},
  title = {The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence‐Based Approach},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3369--3376},
  doi = {10.1111/all.16654}
}
Kostenlos starten →